Biochemical Pregnancy vs Negative Beta: What It Means

When a patient says “I had a biochemical pregnancy,” she sometimes means something different from what the doctor understands. And vice versa. This confusion has important emotional and clinical consequences.

What is a negative beta?

A negative beta means hCG did not rise to detectable levels — or didn’t rise at all. The embryo didn’t implant, or implanted so transiently that it never generated measurable hCG in blood.

Clinically, this is a failed transfer cycle. There is no recordable pregnancy.

What is a biochemical pregnancy?

A biochemical pregnancy occurs when hCG initially rises — the pregnancy exists in biochemical terms — and then falls before anything can be seen on ultrasound (before 5–6 weeks of gestation).

The sequence is: positive hCG → hCG that doesn’t continue rising or falls → loss before ultrasound documentation.

Why does the distinction matter?

Because the emotional impact of “my embryo implanted but didn’t continue” is different from “it didn’t implant.” Neither is less valid as an experience — but they are different situations that deserve different names.

It also has clinical implications: a biochemical pregnancy confirms that implantation occurred; the problem was in subsequent embryonic development. A negative beta confirms nothing about uterine receptivity. The scale of this phenomenon is larger than most patients expect: Macklon, Geraedts and Fauser published what became known as the “black box” paper in Human Reproduction Update (2002), estimating that approximately 25–30% of all IVF pregnancies detected by positive hCG at day 14 end as biochemical pregnancies that never reach clinical stage. They are common precisely because IVF makes early detection possible.

Why do biochemical pregnancies occur?

The most common cause is embryonic aneuploidy: the embryo has an abnormal chromosome count and development stops early. This has nothing to do with progesterone, bed rest, stress, or anything you ate.

Biochemical pregnancy rates increase with maternal age because chromosomal abnormality rates in eggs increase with age. They are lower with donor eggs, regardless of the recipient’s age. An analysis by Kolibianakis and colleagues published in Human Reproduction Update (2004) found that approximately 70–80% of biochemical pregnancies in IVF cycles involve aneuploid embryos — confirming that this is overwhelmingly a chromosomal issue, not a uterine one.

One beta isn’t enough

If the first beta was positive but low, a second beta 48 hours later is essential. hCG should roughly double in that time in a developing pregnancy. An hCG that rises poorly (<66% in 48 hours) or falls raises strong suspicion of a biochemical pregnancy. However, sometimes one that rises adequately in the first week can stall a few days later. This is why it’s important to go step by step, even when that’s not easy.

Testing before 9–11 days post blastocyst transfer can confuse the picture: too early may give a false negative, and residual trigger hCG can give a false positive. Research by Liao and colleagues published in Reproductive BioMedicine Online (2020) provided useful prognostic thresholds for the day 14 beta: values below 50 mIU/mL were associated with greater than 95% pregnancy loss, while values above 300 mIU/mL carried less than 5% loss risk. More important than any single number, however, is the doubling time: a 48-hour doubling of hCG was the most predictive factor for ongoing pregnancy in their analysis.

What comes after

Both a negative beta and a biochemical pregnancy are results that need to be processed — not just medically, but emotionally. The grief of a failed cycle is real. What doesn’t help is rushing to reinterpret or minimize it prematurely.

Case review — what was the embryo quality, what were the endometrial conditions, what happened with progesterone — happens at the follow-up appointment, with a clearer head. Ideally, a few days after the news (not that same day).

Biochemical pregnancy and negative beta are not the same thing. Naming it correctly is the first step toward understanding what happened and what comes next.

Dr. Demián Glujovsky

Written by
Scientific Director at CEGYR Buenos Aires. Cochrane Collaboration reviewer. 50+ peer-reviewed publications in reproductive medicine. Practicing since 2005.